The lipodystrophy syndrome as a risk marker for cardiovascular disease in patients with HIV/AIDS treated with HAART

1Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Introduction: The classic risk factors for cardiovascular disease in healthy individuals are well known, however, it lacks in the literature the mechanisms that predicts cardiovascular disease in the population living with HIV-AIDS treated with HAART and presenting syndrome lipodystrophy. We aimed to investigate the risk of cardiovascular disease in HIV-AIDS patients treated with HAART and lipodystrophy syndrome. Methods: A search was performed in Medline, SciELO, Lilacs and Cochrane using the intersection between the keywords: "cardiovascular disease", "HIV", "AIDS", "HAART" and "lipodystrophy syndrome". Results: The selected studies demonstrated that metabolic disorders such as hyperlipidemia, central adipose hypertrophy and peripheral lipoatrophy, besides the metabolic syndrome and lipodystrophy are maker clear risks of developing cardiovascular disease in these individuals. Conclusion: The metabolic alterations in HIV-AIDS treated with HAART and presenting lipodystrophy syndrome may potentiate the development of cardiovascular diseases.

Cite

CITATION STYLE

APA

Pereira, V. X., De Abreu, L. C., Valenti, V. E., Raimundo, R. D., Da Silva, M. H., Oliveira, F. R., … Ferreira, C. (2015). The lipodystrophy syndrome as a risk marker for cardiovascular disease in patients with HIV/AIDS treated with HAART. International Archives of Medicine, 8(1). https://doi.org/10.3823/1677

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free